Pharma Focus Asia
KP - Sustainable Packaging Solutions

Sanofi to Invest US$410 million in State-of-the-Art Vaccine Facility at Canada


Sanofi Pasteur announced its US$ 410 million investment plan for the construction of a new state-of-the-art vaccine manufacturing facility centre at its Canadian headquarters in Toronto.


The new facility will allow Sanofi Pasteur to increase its capacity to meet the growing demand of five-component acellular pertussis (5-acP) antigen and come one step closer in reducing the number of deaths caused due to vaccine-preventable disease.

The New Toronto Vaccine facility centre is planned to get completed by 2021.

It will be one of the largest investments ever made by Sanofi in a single building which will also have the facility to produce the antigens used in diphtheria and tetanus vaccines.


NameSanofi Pasteur
LocationToronto, Ontario
Estimated BudgetUS$410 million
Parties InvolvedSanofi Pasteur
Latest Issue
Get instant
access to our latest e-book
Standard BioTools™MFA + MMA 2024CPHI Chine || PMEC China 2024Gibco Adherent Kidney Media PanelAsia Healthcare Week 2024CPHI Korea 2024Equinix accelerated medical research...CHEMICAL INDONESIA 2024Thermofisher - Antibody Therapeutic PolishingINALAB 2024 Thermo Scientific - DynaDrive and DynaSpinDigital Health Asia 2024ISPE Singapore Affiliate Conference & Exhibition 2024Rehab Expo 20242024 PDA Pharmaceutical Manufacturing & Quality Conference2024 PDA Cell and Gene Pharmaceutical Products Conference 2024 PDA Aseptic Manufacturing Excellence Conference2024 PDA Aseptic Processing of Biopharmaceuticals ConferencePharma Quality Excellence Awards 20244th Annual Pharma GMP Quality Management 20243rd World ADC Asia 2024
Searching for an end-to-end patient tech solution?